

# Substance (Drug) Abuse - Pipeline Insight, 2020

<https://marketpublishers.com/r/S76F7C9C6D6EN.html>

Date: January 2020

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: S76F7C9C6D6EN

## Abstracts

This report can be delivered to the clients within 48-72 Hours

### Substance (Drug) Abuse Overview

'Substance (Drug) Abuse Pipeline Insight, 2020' Report By DelveInsight Outlays Comprehensive Insights Of Present Clinical Development Scenario And Growth Prospects Across The Substance (Drug) Abuse Market. A Detailed Picture Of The Substance (Drug) Abuse Pipeline Landscape Is Provided, Which Includes The Disease Overview And Substance (Drug) Abuse Treatment Guidelines.

The Assessment Part Of The Report Embraces In-Depth Substance (Drug) Abuse Commercial Assessment And Clinical Assessment Of The Substance (Drug) Abuse Pipeline Products From The Pre-Clinical Developmental Phase To The Marketed Phase.

In The Report, A Detailed Description Of The Drug Is Proffered Including Mechanism Of Action Of The Drug, Clinical Studies, NDA Approvals (If Any), And Product Development Activities Comprising The Technology, Substance (Drug) Abuse Collaborations, Licensing, Mergers And Acquisition, Funding, Designations, And Other Product-Related Details.

### Substance (Drug) Abuse Of Pipeline Development Activities

The Report Provides Insights Into:

All Of The Companies That Are Developing Therapies For The Treatment Of Substance (Drug) Abuse With Aggregate Therapies Developed By Each Company For The Same.

Different Therapeutic Candidates Segmented Into Early-Stage, Mid-Stage And Late Stage Of Development For The Substance (Drug) Abuse Treatment.

Substance (Drug) Abuse Key Players Involved In Targeted Therapeutics

Development With Respective Active And Inactive (Dormant Or Discontinued) Projects.

Drugs Under Development Based On The Stage Of Development, Route Of Administration, Target Receptor, Monotherapy Or Combination Therapy, A Different Mechanism Of Action, And Molecular Type.

Detailed Analysis Of Collaborations (Company-Company Collaborations And Company-Academia Collaborations), Licensing Agreement And Financing Details For Future Advancement Of Substance (Drug) Abuse Market.

The Report Is Built Using Data And Information Traced From The Researcher's Proprietary Databases, Company/University Websites, Clinical Trial Registries, Conferences, SEC Filings, Investor Presentations, And Featured Press Releases From Company/University Web Sites And Industry-Specific Third-Party Sources, Etc.

Substance (Drug) Abuse Analytical Perspective By DelveInsight

In-Depth Substance (Drug) Abuse Commercial Assessment Of Products

This Report Provides A Comprehensive Commercial Assessment Of Therapeutic Drugs That Have Been Included, Which Comprises Of Collaborations, Licensing, And Acquisition Deal Value Trends. The Report Also Covers Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, And Acquisition Analysis In Both Graphical And Tabulated Form In A Detailed Manner.

Substance (Drug) Abuse Clinical Assessment Of Products

The Report Comprises Of Comparative Clinical Assessment Of Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type Across This Indication.

## **SCOPE OF THE REPORT**

The Substance (Drug) Abuse Report Provides An Overview Of Therapeutic

Pipeline Activity And Therapeutic Assessment Of The Products By Development Stage, Product Type, Route Of Administration, Molecule Type, And MOA Type For Substance (Drug) Abuse Across The Complete Product Development Cycle, Including All Clinical And Nonclinical Stages.

It Comprises Of Detailed Profiles Of Substance (Drug) Abuse Therapeutic Products With Key Coverage Of Developmental Activities, Including Technology, Collaborations, Licensing, Mergers And Acquisition, Funding, Designations And Other Product-Related Details

Detailed Substance (Drug) Abuse Research And Development Progress And Trial Details, Results Wherever Available, Are Also Included In The Pipeline Study.

Coverage Of Dormant And Discontinued Pipeline Projects Along With The Reasons If Available Across Substance (Drug) Abuse.

## Report Highlights

A Better Understanding of Disease Pathogenesis Contributing To The Development Of Novel Therapeutics For Substance (Drug) Abuse.

In The Coming Years, The Substance (Drug) Abuse Market Is Set To Change Due To The Rising Awareness Of The Disease, And Incremental Healthcare Spending Across The World; Which Would Expand The Size Of The Market To Enable The Drug Manufacturers To Penetrate More Into The Market.

The Companies And Academics That Are Working To Assess Challenges And Seek Opportunities That Could Influence Substance (Drug) Abuse R&D. The Therapies Under Development Are Focused On Novel Approaches To Treat/Improve The Disease Condition.

A Detailed Portfolio of Major Pharma Players Who Are Involved In Fueling The Substance (Drug) Abuse Treatment Market. Several Potential Therapies For Substance (Drug) Abuse Are Under Investigation. With The Expected Launch Of These Emerging Therapies, It Is Expected That There Will Be A Significant Impact On The Substance (Drug) Abuse Market Size In The Coming Years.

Our In-Depth Analysis Of The Pipeline Assets (In Early-Stage, Mid-Stage And Late Stage Of Development For The Treatment Of Substance (Drug) Abuse ) Includes Therapeutic Assessment And Comparative Analysis. This Will Support The Clients In The Decision-Making Process Regarding Their Therapeutic Portfolio By Identifying The Overall Scenario Of The Research And Development Activities.

## **KEY QUESTIONS**

What Are The Current Options For Substance (Drug) Abuse Treatment?

How Many Companies Are Developing Therapies For The Treatment Of Substance (Drug) Abuse?

What Are The Principal Therapies Developed By These Companies In The Industry?

How Many Therapies Are Developed By Each Company For The Treatment Of Substance (Drug) Abuse?

How Many Substance (Drug) Abuse Emerging Therapies Are In Early-Stage, Mid-Stage, And Late Stage Of Development For The Treatment Of Substance (Drug) Abuse?

Out Of Total Pipeline Products, How Many Therapies Are Given As A Monotherapy And In Combination With Other Therapies?

What Are The Key Collaborations (Industry-Industry, Industry-Academia), Mergers And Acquisitions, And Major Licensing Activities That Will Impact Substance (Drug) Abuse Market?

Which Are The Dormant And Discontinued Products And The Reasons For The Same?

What Is The Unmet Need For Current Therapies For The Treatment Of Substance (Drug) Abuse?

What Are The Recent Novel Therapies, Targets, Mechanisms Of Action And

Technologies Developed To Overcome The Limitation Of Existing Substance (Drug) Abuse Therapies?

What Are The Clinical Studies Going On For Substance (Drug) Abuse And Their Status?

What Are The Results Of The Clinical Studies And Their Safety And Efficacy?

What Are The Key Designations That Have Been Granted For The Emerging Therapies For Substance (Drug) Abuse?

How Many Patents Are Granted And Pending For The Emerging Therapies For The Treatment Of Substance (Drug) Abuse?

## Contents

### **1. REPORT INTRODUCTION**

### **2. SUBSTANCE (DRUG) ABUSE**

- 2.1. Overview
- 2.2. History
- 2.3. Substance (Drug) Abuse Symptoms
- 2.4. Causes
- 2.5. Pathophysiology
- 2.6. Substance (Drug) Abuse Diagnosis
  - 2.6.1. Diagnostic Guidelines

### **3. SUBSTANCE (DRUG) ABUSE CURRENT TREATMENT PATTERNS**

- 3.1. Substance (Drug) Abuse Treatment Guidelines

### **4. SUBSTANCE (DRUG) ABUSE - DELVEINSIGHT'S ANALYTICAL PERSPECTIVE**

- 4.1. In-depth Commercial Assessment
  - 4.1.1. Substance (Drug) Abuse companies collaborations, Licensing, Acquisition -Deal Value Trends
    - 4.1.1.1. Assessment Summary
  - 4.1.2. Substance (Drug) Abuse Collaboration Deals
    - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    - 4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
    - 4.1.2.3. Substance (Drug) Abuse Acquisition Analysis

### **5. THERAPEUTIC ASSESSMENT**

- 5.1. Clinical Assessment of Pipeline Drugs
  - 5.1.1. Assessment by Phase of Development
  - 5.1.2. Assessment by Product Type (Mono / Combination)
    - 5.1.2.1. Assessment by Stage and Product Type
  - 5.1.3. Assessment by Route of Administration
    - 5.1.3.1. Assessment by Stage and Route of Administration
  - 5.1.4. Assessment by Molecule Type
    - 5.1.4.1. Assessment by Stage and Molecule Type

#### 5.1.5. Assessment by MOA

##### 5.1.5.1. Assessment by Stage and MOA

#### 5.1.6. Assessment by Target

##### 5.1.6.1. Assessment by Stage and Target

### **6. SUBSTANCE (DRUG) ABUSE LATE STAGE PRODUCTS (PHASE-III)**

### **7. SUBSTANCE (DRUG) ABUSE MID STAGE PRODUCTS (PHASE-II)**

### **8. EARLY STAGE PRODUCTS (PHASE-I)**

### **9. PRE-CLINICAL PRODUCTS AND DISCOVERY STAGE PRODUCTS**

### **10. INACTIVE PRODUCTS**

### **11. DORMANT PRODUCTS**

### **12. SUBSTANCE (DRUG) ABUSE DISCONTINUED PRODUCTS**

### **13. SUBSTANCE (DRUG) ABUSE PRODUCT PROFILES**

#### 13.1. Drug Name: Company

##### 13.1.1. Product Description

###### 13.1.1.1. Product Overview

###### 13.1.1.2. Mechanism of action

##### 13.1.2. Research and Development

###### 13.1.2.1. Clinical Studies

##### 13.1.3. Product Development Activities

###### 13.1.3.1. Collaboration

###### 13.1.3.2. Agreements

###### 13.1.3.3. Acquisition

###### 13.1.3.4. Patent Detail

##### 13.1.4. Tabulated Product Summary

###### 13.1.4.1. General Description Table

Detailed information in the report?

### **14. SUBSTANCE (DRUG) ABUSE KEY COMPANIES**

### **15. SUBSTANCE (DRUG) ABUSE KEY PRODUCTS**

## **16. DORMANT AND DISCONTINUED PRODUCTS**

### 16.1. Dormant Products

#### 16.1.1. Reasons for being dormant

### 16.2. Discontinued Products

#### 16.2.1. Reasons for the discontinuation

## **17. SUBSTANCE (DRUG) ABUSE UNMET NEEDS**

## **18. SUBSTANCE (DRUG) ABUSE FUTURE PERSPECTIVES**

## **19. SUBSTANCE (DRUG) ABUSE ANALYST REVIEW**

## **20. APPENDIX**

## **21. REPORT METHODOLOGY**

### 21.1. Secondary Research

### 21.2. Expert Panel Validation



## List Of Tables

### LIST OF TABLES

- Table 1: Substance (Drug) Abuse Diagnostic Guidelines
- Table 2: Substance (Drug) Abuse Treatment Guidelines
- Table 3: Assessment Summary
- Table 4: Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5: Substance (Drug) Abuse Acquisition Analysis
- Table 6: Assessment by Phase of Development
- Table 7: Assessment by Product Type (Mono / Combination)
- Table 8: Assessment by Stage and Product Type
- Table 9: Assessment by Route of Administration
- Table 10: Assessment by Stage and Route of Administration
- Table 11: Assessment by Molecule Type
- Table 12: Assessment by Stage and Molecule Type
- Table 13: Assessment by MOA
- Table 14: Assessment by Stage and MOA
- Table 15: Assessment by Target
- Table 16: Assessment by Stage and Target
- Table 17: Substance (Drug) Abuse Late Stage Products (Phase-III)
- Table 18: Substance (Drug) Abuse Mid Stage Products (Phase-II)
- Table 19: Substance (Drug) Abuse Early Stage Products (Phase-I)
- Table 20: Pre-clinical and Discovery Stage Products
- Table 21: Inactive Products
- Table 22: Dormant Products
- Table 23: Discontinued Products

## List Of Figures

### LIST OF FIGURES

- Figure 1: Disease Overview
- Figure 2: History
- Figure 3: Symptoms
- Figure 4: Causes
- Figure 5: Pathophysiology
- Figure 6: Diagnostic Guidelines
- Figure 7: Treatment Guidelines
- Figure 8: Substance (Drug) Abuse companies collaborations, Licensing, Acquisition -Deal Value Trends
- Figure 9: Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10: Substance (Drug) Abuse Acquisition Analysis
- Figure 11: Assessment by Phase of Development
- Figure 12: Assessment by Product Type (Mono / Combination)
- Figure 13: Assessment by Stage and Product Type
- Figure 14: Assessment by Route of Administration
- Figure 15: Assessment by Stage and Route of Administration
- Figure 16: Assessment by Molecule Type
- Figure 17: Assessment by Stage and Molecule Type
- Figure 18: Assessment by MOA
- Figure 19: Assessment by Stage and MOA
- Figure 20: Late Stage Products (Phase-III)
- Figure 21: Mid Stage Products (Phase-II)
- Figure 22: Early Stage Products (Phase-I)
- Figure 23: Pre-clinical and Discovery Stage Products
- Figure 24: Inactive Products
- Figure 25: Dormant Products
- Figure 26: Discontinued Products
- Figure 27: Unmet Needs

## I would like to order

Product name: Substance (Drug) Abuse - Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/S76F7C9C6D6EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S76F7C9C6D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970